Bicara Therapeutics Inc. filings document the regulatory record of a clinical-stage biopharmaceutical issuer developing bifunctional therapies for solid tumors. Forms 8-K record financial results, business highlights, ficerafusp alfa clinical updates, material definitive agreements and other events, including common stock and pre-funded warrant financing.
The company’s proxy materials cover annual meeting proposals, board-class elections, auditor ratification and governance matters for an emerging growth company. The filings also describe capital-structure actions and formal exhibits tied to press releases, underwriting agreements and shareholder voting matters.
Janus Henderson Group plc reported beneficial ownership of 3,339,218 shares of Bicara Therapeutics Inc. (Common Stock), representing 5.1% of the class as of 03/31/2026 in a Schedule 13G filing. The filing states these holdings arise from discretionary management of client portfolios and that the Asset Managers disclaim rights to dividends or sale proceeds.
Bicara Therapeutics Schedule 13G/A shows Deep Track-related reporting persons beneficially own 4,062,500 shares of common stock, representing 6.21% of the class. The filing states 65,467,187 shares outstanding as of March 24, 2026 (issuer 10-K). The ownership is reported as shared voting and dispositive power and is reported by Deep Track Capital, LP, Deep Track Biotechnology Master Fund, Ltd., and David Kroin.
Bicara Therapeutics Inc. reported that Chief Medical Officer William Schelman received a grant of stock options covering 85,000 shares of common stock. The options have an exercise price of $22.58 per share and expire on May 8, 2036.
According to the terms, the shares underlying this option vest in sixteen equal quarterly installments following May 8, 2026, contingent on his continued service. After this grant, Schelman holds options for 85,000 shares directly, reflecting a routine compensation-related award rather than an open-market trade.
Bicara Therapeutics Inc. reported initial insider holdings for Chief Medical Officer William Schelman on a Form 3. He holds stock options to acquire 25,000 shares of common stock at an exercise price of $16.76 per share, expiring on February 2, 2036, and options over 150,000 shares at $16.61 per share, expiring on October 1, 2035. These options vest over time, with one grant vesting 25% on October 1, 2026 and the balance in twelve quarterly installments, and the other vesting in sixteen equal quarterly installments following February 2, 2026, all subject to his continued service.
Bicara Therapeutics reports a larger quarterly loss as it accelerates development of its lead cancer drug ficerafusp alfa. For the three months ended March 31, 2026, net loss was $56.2 million, or $0.93 per share, compared with $36.8 million, or $0.68 per share, a year earlier.
Research and development expenses rose to $47.5 million from $34.3 million, driven by manufacturing and clinical costs for the Phase 2/3 FORTIFI-HN01 pivotal trial and Phase 1/1b studies. General and administrative expenses increased to $12.7 million from $7.5 million as the company expanded headcount and public-company infrastructure.
Cash, cash equivalents and marketable securities totaled $539.8 million as of March 31, 2026, supported by a February 2026 equity and pre-funded warrant offering that generated about $161.8 million in net proceeds. Management believes this liquidity can fund operations into the first half of 2029 while Bicara advances ficerafusp alfa toward potential regulatory milestones.
Bicara Therapeutics reported first quarter 2026 results and highlighted progress advancing its lead cancer asset ficerafusp alfa. Cash, cash equivalents and marketable securities were $539.8 million as of March 31, 2026, up from $414.8 million at December 31, 2025, helped by approximately $161.8 million in net proceeds from an oversubscribed public offering. The company expects this cash to fund operations into the first half of 2029.
Research and development expenses rose to $47.5 million from $34.3 million a year earlier, and general and administrative expenses increased to $12.7 million from $7.5 million, reflecting pivotal FORTIFI-HN01 trial costs, Phase 1/1b expansions and higher personnel and professional fees. Net loss widened to $56.2 million, or $0.93 per share, compared with $36.8 million, or $0.68 per share, in the prior-year quarter.
Operationally, Bicara continued enrollment in its pivotal FORTIFI-HN01 trial in first-line HPV-negative head and neck cancer and plans a randomized alternate-dose study of ficerafusp alfa with pembrolizumab starting in the third quarter of 2026. The company expects to present long-term Phase 1b data at ASCO 2026 and additional data in other solid tumors later in 2026. Leadership changes included promoting Bill Schelman to Chief Medical Officer and appointing Chris Sarchi as Chief Commercial Officer to support potential commercialization.
BICARA THERAPEUTICS INC. owners Red Tree GP, LLC; Red Tree Venture Fund, L.P.; and Heath Lukatch filed an amendment to a Schedule 13G/A reporting beneficial ownership of 3,170,509 shares of common stock as of March 31, 2026. The filing reports this equals 4.8% of the class based on 65,467,187 shares outstanding as of March 24, 2026. The filing states Red Tree Fund I holds the shares directly, Red Tree GP I is the general partner, and Lukatch, as managing director, possesses shared voting and dispositive power over those shares.
FMR LLC amended its Schedule 13G/A to report beneficial ownership of 2,100,929 shares of Bicara Therapeutics Inc. (BCAX), representing 3.2% of the class. The filing lists sole voting power of 2,100,241 shares and sole dispositive power of 2,100,929. The cover identifies the CUSIP as 055477103 and cites a Power of Attorney incorporated by reference.
Bicara Therapeutics Chief Medical Officer David Raben reported an option exercise and related share sale. He exercised stock options for 5,500 shares of common stock at an exercise price of $3.7898 per share, then sold 5,500 shares in an open-market transaction at a weighted average price of $22.8782 per share.
The sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on February 12, 2025, and occurred through multiple trades between $22.51 and $23.07 per share. Following these transactions, Raben directly holds 55,286 shares of common stock and 41,913 stock options.
BCAX submitted a Form 144 reporting 5,500 shares of Common Stock to be sold on 04/27/2026 following an exercise of stock options. The sale is listed through UBS Financial Services Inc. and is to be for cash. The filing also lists prior sales by David Raben in March 2026: 200 shares on 03/03/2026 for $3,690.00, 16,300 shares on 03/04/2026 for $301,920.01, and 5,500 shares on 03/25/2026 for $104,229.40.